Q1 2024 EPS Estimates for Danaher Co. Decreased by Analyst (NYSE:DHR)

Danaher Co. (NYSE:DHR) – Zacks Research cut their Q1 2024 EPS estimates for shares of Danaher in a report released on Wednesday, April 17th. Zacks Research analyst R. Department now anticipates that the conglomerate will post earnings per share of $1.72 for the quarter, down from their previous forecast of $1.74. The consensus estimate for Danaher’s current full-year earnings is $7.62 per share. Zacks Research also issued estimates for Danaher’s Q2 2024 earnings at $1.62 EPS, Q3 2024 earnings at $1.90 EPS, Q4 2024 earnings at $2.34 EPS, Q3 2025 earnings at $2.14 EPS, Q4 2025 earnings at $2.42 EPS, FY2025 earnings at $8.47 EPS, Q1 2026 earnings at $2.25 EPS and FY2026 earnings at $10.01 EPS.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.18. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The firm had revenue of $6.41 billion during the quarter, compared to the consensus estimate of $6.10 billion. During the same period last year, the firm posted $2.87 EPS. The firm’s quarterly revenue was down 10.2% on a year-over-year basis.

Several other equities research analysts have also recently weighed in on DHR. Barclays raised their price objective on shares of Danaher from $240.00 to $260.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 10th. Raymond James raised their price objective on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. KeyCorp raised their price objective on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Royal Bank of Canada raised their price objective on shares of Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Finally, HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and lifted their price target for the stock from $250.00 to $280.00 in a research report on Wednesday. Six research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $268.27.

Danaher Trading Down 1.3 %

Shares of DHR stock opened at $236.37 on Thursday. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $175.04 billion, a P/E ratio of 36.99, a P/E/G ratio of 3.65 and a beta of 0.83. Danaher has a 12-month low of $182.09 and a 12-month high of $259.00. The firm has a 50-day moving average price of $249.09 and a 200 day moving average price of $229.90.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be issued a dividend of $0.27 per share. The ex-dividend date is Wednesday, March 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.46%. This is a boost from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is currently 16.90%.

Insider Activity at Danaher

In related news, Director Teri List sold 3,289 shares of the business’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the transaction, the director now owns 19,726 shares in the company, valued at $4,898,360.32. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Danaher news, Director Teri List sold 3,289 shares of Danaher stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the transaction, the director now owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Daniel Raskas sold 23,757 shares of Danaher stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the transaction, the senior vice president now directly owns 38,102 shares in the company, valued at approximately $9,601,704. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,957 shares of company stock worth $8,265,802. 11.10% of the stock is currently owned by company insiders.

Institutional Trading of Danaher

A number of institutional investors have recently made changes to their positions in DHR. Fairfield Bush & CO. raised its position in Danaher by 10.9% during the first quarter. Fairfield Bush & CO. now owns 4,840 shares of the conglomerate’s stock worth $1,420,000 after acquiring an additional 475 shares in the last quarter. Zions Bancorporation N.A. raised its position in Danaher by 19.3% during the first quarter. Zions Bancorporation N.A. now owns 2,468 shares of the conglomerate’s stock worth $724,000 after acquiring an additional 400 shares in the last quarter. Covestor Ltd raised its position in Danaher by 76.8% during the first quarter. Covestor Ltd now owns 495 shares of the conglomerate’s stock worth $145,000 after acquiring an additional 215 shares in the last quarter. NewEdge Advisors LLC raised its position in Danaher by 14.1% during the first quarter. NewEdge Advisors LLC now owns 31,530 shares of the conglomerate’s stock worth $9,248,000 after acquiring an additional 3,897 shares in the last quarter. Finally, Bridgewater Associates LP raised its position in Danaher by 135.9% during the first quarter. Bridgewater Associates LP now owns 35,270 shares of the conglomerate’s stock worth $10,346,000 after acquiring an additional 20,320 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.